TP53 and acute myeloid leukemia: The adverse TP53 Mut AML patients in our study had the lowest CR rate (p = 0.0065) and an even worse OS (median OS 7.8 months; p = 0.0036), distinguishing them from the other adverse genotypes, referred to as adverse TP53 WT AML.